Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...